


Pharmaceuticals & Biotechnology | Small Cap
Zenith Drugs Ltd demonstrates a mixed financial performance. The company shows strength in solvency and profitability. However, liquidity, efficiency, and growth metrics are concerning. The company has low debt levels, indicating financial stability and reduced risk. Profitability ratios such as ROCE, ROE, and margins are strong, suggesting efficient operations and good earnings generation. Poor liquidity indicates potential difficulties in meeting short-term obligations. Inefficiency in asset utilization and a significant drop in revenue, operating profit, EPS, assets, and net income indicate the company is facing serious challenges. There is a moderate ability to cover interest and dividends. The company has poor EPS and book value per share, but manages capital expenditures reasonably well.
Zenith Drugs Ltd demonstrates a mixed financial performance. The company shows strength in solvency and profitability. However, liquidity, efficiency, and growth metrics are concerning. The company has low debt levels, indicating financial stability and reduced risk. Profitability ratios such as ROCE, ROE, and margins are strong, suggesting efficient operations and good earnings generation. Poor liquidity indicates potential difficulties in meeting short-term obligations. Inefficiency in asset utilization and a significant drop in revenue, operating profit, EPS, assets, and net income indicate the company is facing serious challenges. There is a moderate ability to cover interest and dividends. The company has poor EPS and book value per share, but manages capital expenditures reasonably well.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
19.13
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
7.87
P/B RATIO
1.21
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
0.54
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
4.16
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹44 as on Aug 6, 2026.
The company's growth ratios are negative, indicating significant challenges. Declines in revenue, operating profit, EPS, assets, and net income suggest business contraction. This could reflect market challenges or internal operational issues. The negative growth rates raise concerns about the company's future prospects and sustainability. Focus needs to be on identifying the root causes of decline and implementing corrective strategies.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Revenue Growth Rate | 23.91 | 14.91 | |
| Operating Profit Growth Rate | 28.57 | 88.89 | |
| Earnings Per Share (EPS) Growth | |||
| Asset Growth Rate | 42.03 | 37.76 | |
| Net Income Growth Rate | 66.67 | 100 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 9.48 | Undervalued | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 24.94 | Neutral | 4.00 | 0.31 | 4.00 |
| 3 | Mono Pharmacare Ltd | 6.16 | 4.71 | Neutral | 8.00 | 1.75 | 3.00 |
| 4 | JFL Life Sciences Ltd | 6.07 | 13.51 | Neutral | 12.00 | 1.94 | 6.00 |
| 5 | Quest Laboratories Ltd | 5.27 | 9.84 | Neutral | 18.00 | 9.16 | 15.00 |
| 6 | Sotac Pharmaceuticals Ltd | 5.27 | 18.18 | Neutral | 18.00 | 4.45 | 6.00 |
| 7 | Zenith Drugs Ltd | 4.63 | 7.87 | Neutral | 17.00 | 2.30 | 10.00 |
| 8 | Mangalam Drugs and Organics Ltd | 4.50 | -0.97 | Neutral | -15.00 | -27.68 | -44.00 |
| 9 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 10 | Krebs Biochemicals & Industries Ltd | 4.16 | -4.34 | Highly Undervalued | -4.00 | -7.85 | -4.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish